What Do You Really Know About Psychedelics And Psychedelics Stocks?
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use.
These OTC Securities Had the Most Trading Activity in July
Photo by Federico Beccari on Unsplash
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.
HC Wainwright & Co. Initiates Coverage On Cybin with Buy Rating, Announces Price Target of $8
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Cybin (OTC:CLXPF) with a Buy rating and announces Price Target of $8.
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To “Psychedelics Renaissance”
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
These OTC Securities Had the Most Trading Activity in June
Photo by Cris Ovalle on Unsplash
OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as volumes in crypto and cannabis slowed.
Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of Mescaline?
Aegis Capital Initiates Coverage On Cybin with Buy Rating, Announces Price Target of $9
Aegis Capital analyst Nathan Weinstein initiates coverage on Cybin (OTC:CLXPF) with a Buy rating and announces Price Target of $9.